Phase 3 RCT in 531 patients with untreated, driver gene-negative, PD-L1-positive advanced NSCLC: benmelstobart plus anlotinib lengthened median PFS vs pembrolizumab (11.0 vs 7.1 months; HR 0.70). Grade ≥3 treatment-related adverse events were 59% vs 29%.
RCTn = 531 patients
Zhong et al. Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial